Data Sheet 1_Vibroacoustic lung therapy and early postoperative oxygenation after cardiac surgery: a multicentre prospective study.pdf

Key secondary outcomes included FiO₂ requirement, SpO₂, PaO₂, PaCO₂, acid–base status parameters, clinical scales, radiographic findings, length of stay, and recorded safety outcomes.</p>Results<p>Of 354 screened patients, 317 were included in the analysis: 156 in the VibroLUNG group and 161 in the control group. Baseline anthropometric characteristics were comparable; however, the distribution by center/region differed substantially between the groups.

At the early postoperative assessment, the VibroLUNG group had a lower administered FiO₂ [35.0% [30.0–41.0] vs. 41.5% [40.0–50.0], p < 0.001]. In the principal centre-adjusted analysis, the P/F ratio was higher in the VibroLUNG group by 23.8 units (95% CI 8.1–39.5; p=0.003). Before extubation, FiO₂ remained lower in the VibroLUNG group [30.0% [30.0–35.0] vs. 35.0% [30.0–50.0], p < 0.001], whereas the unadjusted difference in the P/F ratio was not statistically significant.

No device-related adverse events, device deficiencies, or deaths during study participation were recorded.</p>Conclusion<p>VibroLUNG use was associated with a higher early postoperative P/F ratio and lower administered FiO₂. No adverse events, device deficiencies, or deaths were recorded during the study observation period. Causal inference is limited by the non-randomized design and centre-level differences.</p>